

IN THE CLAIMS:

Cancel all previous pending claims without prejudice.

Add the following new claims:

SUB
E1
c 12
1
+20. (new) A cell composition comprising macrophages, wherein said macrophages are present in an amount of about 10 to about 70%, said percentage being expressed with respect to the total number of cells, and wherein said composition exhibits anti-infectious and hematopoietic properties.

+21. (new) The cell composition according to claim 20, further comprising progenitor cells, said progenitor cells are present in an amount of, at least 0.1%, said percentage being expressed with respect to the total number of cells.

SUB
E2
+22. (new) The cell composition according to claim 20, further comprising progenitor cells, said progenitor cells are present in an amount of about 0.1 to about 20%, said percentage being expressed with respect to the total number of cells.

+23. (new) The cell composition according to claim 20, further comprising myeloid cells, said myeloid cells are present

in an amount of about 10% to about 30%, said percentage being expressed with respect to the total number of cells.

~~24.~~ (new) The cell composition according to claim 20, further comprising myeloid cells and progenitor cells, said progenitor cells are present in an amount of at least about 0.1%, said myeloid cells are present in an amount of about 10% to about 30%, said percentages are expressed with respect to the total number of cells.

~~25.~~ (new) The cell composition according to claim 20, further comprising T lymphocytes in an amount of about 10 to 60% expressed with respect to the total number of cells.

SUB
E 3 → ~~26.~~ (new) The cell composition according to claim 21, wherein said progenitor cells contain from about 0.1 to about 20% of stem cells, expressed with respect to the total number of progenitor cells.

~~27.~~ (new) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 20.

~~28.~~ (new) The cell composition according to claim 20, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

~~29.~~ (new) The cell composition according to claim 22, further comprising T lymphocytes, in an amount of about 10 to 60% expressed with respect to the total number of cells.

~~30.~~ (new) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 22.

~~31.~~ (new) The cell composition according to claim 22, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

--32. (new) A cell composition comprising macrophages, myeloid cells and progenitor cells, said progenitor cells are present in an amount of about 0.1% to about 20%, said macrophages are in an amount of about 10 to about 70%, and said percentages are expressed with respect to the total number of cells, as obtained by a process comprising the following steps:

- collecting mononuclear cells and progenitors by apheresis

- co-culturing blood mononuclear cells and progenitors, after washing of platelets, granulocytes and erythrocytes, for 4 to 10 days, in a medium allowing differentiation of monocytes into macrophages and myeloid progenitors into polynuclear cells.

--33. (new) A cell composition comprising macrophages, myeloid cells and progenitor cells, wherein said progenitor cells are present in an amount of about 0.1% to about 20%, said macrophages being in an amount of about 10 to about 70%, said percentages are expressed with respect to the total number of cells, as obtained by a process comprising the following steps:

- mobilizing progenitor cells in the blood of a patient by premedication of said patient with G-CSF and/or GM-CSF or G-CSF and cyclophosphamide,

- collecting mononuclear cells and progenitors by apheresis,